HR 6852119th CongressIn Committee
Advanced Wound Care and Regenerative Medicine Access and Reform Act
Standard Summary
Balanced plain-English summary
This bill would amend Medicare to cover skin substitute products, set a new payment methodology based on volume-weighted average payment limits and annual CPI updates, require equivalent reimbursement across outpatient sites, strengthen program integrity through outlier review and prior authorization, and direct FDA to streamline review of certain human cell and tissue products.
Key Points
- 1Adds Medicare coverage and a new payment methodology for skin substitute products beginning in 2026.
- 2Creates a consolidated billing and payment code for skin substitute products.
- 3Establishes outlier provider identification, prepayment review, prior authorization, and possible exclusion for noncompliant providers.
- 4Limits payment for skin substitute product wastage and requires equivalent reimbursement regardless of outpatient site of care.
- 5Directs FDA to review and streamline approval processes for certain human cellular and tissue-based products.
Impact Areas
Medicare beneficiariesWound care patientsSkin substitute product manufacturersHealthcare providersCMS and FDA
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026